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Background/Aims: Decay of hepatitis B surface antigen (HBsAg) titers has previously been shown to be predictive of a 
virologic response (VR), especially during peginterferon-alpha therapy. However, the role of HBsAg levels in predicting 
a VR to nucleos(t)ide analog therapy has not yet been established. In this study we sought to determine whether the VR 
can be predicted from HBsAg titers in nucleos(t)ide-naïve chronic hepatitis B (CHB) patients treated with entecavir. 
Methods: CHB patients who started entecavir as an initial antiviral therapy were enrolled in this study. Serum hepatitis B 
virus (HBV) DNA, HBsAg, and alanine aminotransferase levels were measured every 3 months during treatment. A VR 
was defined as undetectable serum HBV DNA titer by real-time PCR assay (<60 IU/mL). Results: Fifty-two patients were 
enrolled, and the median duration of treatment was 26 months (range 7-35 months). Forty-five patients achieved a VR; the 
cumulative VR rates at 3, 6, 12, and 24 months were 40%, 71.2%, 81.5%, and 88%, respectively. Baseline HBV DNA 
levels were significantly lower in patients with VR, whereas the HBsAg levels did not differ significantly between patients 
with or without VR. In a univariate analysis the cumulative VR rate was significantly higher in HBeAg negative patients and 
patients with an HBsAg/HBV DNA ratio above 0.56. However, in a multivariate analysis only an HBsAg/HBV DNA ratio 
above 0.56 was an independent predictor of VR (P=0.003). The area under the receiver operating characteristic curve was 
larger for the HBsAg/HBV DNA ratio than for either HBV DNA or HBsAg. Conclusions: Pretreatment HBsAg/HBV DNA 
ratio can predict a long-term VR to entecavir therapy in nucleos(t)ide-naïve CHB patients. (Korean J Hepatol 2011;17: 
268-273)
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INTRODUCTION
The long-term goal of treatment of chronic hepatitis B 
(CHB) is to prevent progression of the disease to cirrhosis, 
hepatic failure, and hepatocellular carcinoma.
1,2 In order to 
assess treatment response, however, quantitative hepatitis B 
virus (HBV) DNA tests are used as a surrogate marker.
1 
Because incomplete suppression of HBV DNA may lead 
to emergence of resistant strains during prolonged oral 
nucleos(t)ide analog (NA) therapy, early viral suppression 
(undetectable serum HBV DNA levels at 24 weeks of 
treatment) is an important predictor of long-term viral 
suppression without viral resistance,
3 especially for NAs 
with low genetic barriers such as lamivudine
4,5 or telbivudine.
6-8
Entecavir is a potent inhibitor of HBV replication with 
higher genetic barrier,
9 and entecavir resistance is as low as 
1.2% in 5 years in antiviral-naïve CHB patients.
10 However, 
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(HBeAg) positive patients still have detectable viral DNA at 
week 48 and 96 of entecavir therapy, respectively.
10-13 It is 
not certain whether lack of early viral suppression can 
predict poor responders to long-term entecavir therapy. 
Meanwhile, pre-treatment serum HBV DNA level is a 
significant predictor of virologic response to entecavir on 
week 48 by our data.
14
Recently, hepatitis B virus surface antigen (HBsAg) 
levels have been studied as a potential predictor of virologic 
response after pegylated-interferon (peg-IFN) alpha therapy 
for CHB: in HBeAg negative CHB patients, virologic response 
to peg-IFN is associated with significant decline in HBsAg 
levels.
15-17 On the other hand, the significance of on-treatment 
changes in HBsAg levels during oral NAs has not been fully 
studied: HBsAg levels were not changed during lamivudine 
therapy,
15 whereas recent studies reported association between 
serum HBsAg drop and viral suppression after telbivudine
18,19 
or entecavir therapy.
20,21 A recent study also reported 
association between pre-treatment HBsAg titers and 
virologic response to entecavr in HBeAg-positive CHB,
21 
but this finding needs further validation. In this study, we 
sought to elucidate whether long-term virologic response 
can be predicted from pre-treatment HBsAg titers, especially 
with relation to HBV DNA levels in nucleos(t)ide-naïve 
CHB patients treated with entecavir.
PATIENTS AND METHODS
Patients and study design
This is a retrospective, cohort study of consecutive 
NA-naïve CHB patients who started entecavir (0.5 mg/day) 
and maintained for at least 6 months between January 2008 
and January 2010 at Seoul National University Bundang 
Hospital. All patients had serum HBV DNA levels greater 
than 357 IU/mL for more than six months before enrollment. 
Serum alanine aminotransferase (ALT) levels were more 
than 1.3-fold the upper normal limit. Exclusion criteria 
included the presence of hepatocellular carcinoma (HCC), 
decompensated liver cirrhosis, hepatitis C or D co-infection, 
and noncompliance. The institutional review board of Seoul 
National University Bundang Hospital approved this study 
(IRB no: B-1006-103-114) which was conducted according 
to the guidelines of the Declaration of Helsinki.
Laboratory tests
Baseline serum HBsAg was quantified using an Architect 
HBsAg assay (Abbott Laboratories, Abbott Park, IL, USA) 
according to the manufacturer’s protocol. Serum HBV DNA 
level was determined by real-time PCR (lower limit of 
quantification = 60 IU/mL; Roche TaqMan HBV test, Roche 
Diagnostics, Basel, Switzerland). Serum HBV DNA and 
ALT levels were measured every 3 months after entecavir 
treatment began. Virologic response (VR) was defined as 
undetectable serum HBV DNA by real-time PCR assay (< 
60 IU/mL).
3,22 Enzyme-linked immunosorbent assay was 
used to test HBeAg state. 
Statistical analysis
Continuous variables which did not show normal 
distribution were expressed as the median with range. 
Differences in baseline characteristics between the patient 
group with or without HBeAg and VR were analyzed using 
Student t-test or Mann-Whitney rank sum test for continuous 
variables and the χ
2 test for categorical variables. Pearson’s 
correlation coefficient was tested for correlation between 
two variables. Area under the receiver operating characteristic 
(ROC) curve was calculated as previously reported
23 
to assess the predictive value of pre-treatment variables 
for VR using Medicalc version 11 (Medicalc software, 
Mariakerke, Belgium). A two-tailed P-value <0.05 was 
considered statistically significant.
RESULTS
Clinical characteristics
Fifty two treatment-naïve chronic hepatitis B patients 
were enrolled during the study period, and six patients were 
lost to follow up after 6 months of entecavir therapy. The 
median duration of treatment was 26 months (range: 7-35 
months). The baseline characteristics of these patients are 
summarized in Table 1. The baseline HBV DNA levels were 
significantly higher in the HBeAg-positive group than in the 
HBeAg-negative group (P=0.001). The HBsAg levels were 
similar between HBeAg-positive and negative groups. 
However, the ratio of baseline HBsAg titer to HBV DNA 
level (“HBsAg/HBV DNA ratio”, log10 [HBsAg]/log10 
[HBV DNA]) was significantly higher in the HBeAg-negative 
patients (P=0.01).270  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
Table 1. Baseline characteristics of the patients
Parameter 
Overall
(n=52)
HBeAg (+)
(n=32)
HBeAg (-)
(n=20)
P-value
Age (year)  47 (20-73) 46 (27-66) 50.5 (20-73) 0.197
*
Gender (M/F) 36/16 23/9 13/7 0.601
†
Cirrhosis (N, %)  26 (49) 11 (33) 15 (75) 0.004
†
ALT (IU/L)  103 (15-565) 114 (15-565) 96.5 (28-258) 0.342
*
HBV DNA (log10  IU/mL) 6.81 (3.04-7.59) 7.25 (3.04-7.59) 5.95 (3.95-7.25) 0.001
*
HBsAg (log10  IU/mL) 3.78 (2.40-3.94) 3.76 (2.40-3.94) 3.80 (3.47-3.90) 0.071
*
HBsAg/HBV DNA ratio
‡ 0.54 (0.33-1.26) 0.51 (0.33-1.26) 0.64 (0.48-0.97) <0.001
*
The data are expressed as the median (range) except gender and cirrhosis. 
*HBeAg (+) vs. HBeAg (-) by Mann-Whitney rank sum test, 
†HBeAg (+) vs. HBeAg (-) by χ
2 test, 
‡ log10 [HBsAg] / log10 [HBV DNA].
ALT, alanine aminotransferase; HBV, hepatitis B virus; HBsAg, hepatitis B virus surface antigen.
Figure 1.  Cumulative rates of a virologic response (VR) to 
entecavir therapy.
Table 2. Characteristics of chronic hepatitis B patients with or without a virologic response (VR) to entecavir therapy
Parameters
VR (+)
(n=45)
VR (-)
(n=7)
P-value
Age (year) 47 (20-73) 47 (35-52) 0.579
*
Gender (M/F) 29/16 7/0 0.058
†
Liver cirrhosis (%) 24 (53) 2 (25) 0.223
†
HBeAg positive (%) 26 (58) 6 (85) 0.158
†
ALT (IU/L) 101 (15-565) 138 (50-398) 0.571
*
HBV DNA (log10 IU/mL) 6.72 (3.04-7.59) 7.25 (5.96-7.25) 0.013
*
HBsAg (log10  IU/mL) 3.79 (2.40-3.94) 3.34 (2.87-3.87) 0.278
*
HBsAg/HBV DNA ratio
‡ 0.56 (0.33-1.26) 0.48 (0.40-0.56) 0.001
*
The data are expressed as the median (range) except gender, cirrhosis and HBeAg positivity.
* VR (+) vs. VR (-) by Mann-Whitney rank sum test, 
† VR (+) vs. VR (-) by χ
2 test, 
‡ log10  [HBsAg]/log10  [HBV DNA].
ALT, alanine aminotransferase; HBV, hepatitis B virus; HBsAg, hepatitis B virus surface antigen.
Virologic response to entecavir therapy and 
predictors 
At 3,6,12 and 24 months, cumulative virologic response 
rates were 40.0%, 71.2%, 81.5%, and 88.0%, respectively 
(Fig. 1). When baseline characteristics were compared 
according to VR, VR (+) group showed significantly lower 
HBV DNA levels and higher HBsAg/HBV DNA ratio 
(P=0.013, 0.001, respectively; Table 2). However, HBsAg 
levels were not significantly different between VR (+) and 
VR (-) groups (P=0.278; Table 2). Univariate analysis showed 
that the VR rate was significantly higher in HBeAg-negative 
patients (55%, 85% and 95% at 3,6 and 12 months, 
respectively) compared to that in HBeAg-positive patients 
(34.4%, 62.5% and 76.1% at 3,6 and 12 months, respectively; Joon Chang Song, et al. HBsAg/HBV DNA ratio predicts a virologic response to entecavir  271
   
   
Figure 2. Univariate analysis of a VR to entecavir therapy. The cumulative VR to entecavir was analyzed by the Kaplan-Meier method 
and compared by the log-rank test according to (A) HBeAg positivity, (B) gender, (C) presence of cirrhosis, (D) baseline alanine 
aminotransferase (cutoff=80 IU/L), (E) baseline serum HBV DNA (cutoff=5×log10 IU/mL), and (F) HBsAg/HBV DNA ratio 
(cutoff=0.56).
Table 3. Cox multivariate regression analysis of factors associated
with a virologic response to entecavir therapy
Parameters Hazard ratio P-value
Age 0.960 0.238
Male 0.421 0.205
Liver cirrhosis 1.311 0.831
HBeAg negative 1.347 0.652
ALT
* 1.593 0.589
HBsAg/HBV DNA ratio
† 2.239 0.003
*<80 IU/L vs. >80 IU/L, 
† >0.56 vs. <0.56.
ALT, alanine aminotransferase; HBV, hepatitis B virus; HBsAg, 
hepatitis B virus surface antigen.
P=0.043; Fig. 2A). Gender, presence of cirrhosis, and ALT 
level were not significant predictors of VR (P=0.223, 0.261, 
0.39, respectively; Fig. 2B-D), whereas low pre-treatment 
serum HBV DNA level was associated with higher VR, 
although the statistical significance was marginal (P=0.059, 
Fig. 2F). The HBsAg/HBV DNA ratio categorized by the 
cut-off value of 0.56 was significantly associated with VR to 
entecavir therapy: cumulative VR rate at 6 and 12 months 
were 87.5% and 100%, respectively, in patients with the 
ratio ≥0.56, and 57.1% and 71.4%, respectively, in patients 
with the ratio <0.56. (P=0.002; Fig. 2F). 
After HBeAg positivity was adjusted by multivariate 
analysis (Cox proportional hazard model), the high HBsAg/ 
HBV DNA ratio was still an independent predictor of VR to 
entecavir therapy (Hazard ratio=2.239, P=0.003; Table 3).  Receiver operating characteristic curve analysis of 
HBV replicative parameters for virologic response 
to entecavir therapy
When the predictive power of HBV replicative parameters 
ABC
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Figure 3. Receiver operating characteristic curve analysis of 
baseline parameters in predicting a VR to entecavir therapy. P
addresses the null hypothesis that the area under the curve 
(AUC) is equal to 0.5. The HBsAg/HBV DNA ratio shows the 
best performance at a cutoff value of 0.56.
were analyzed and compared by receiver operating charac-
teristic curve (ROC) analysis, the HBsAg/HBV DNA ratio 
showed the highest area under the curve (AUC) value 
(0.728; 95% confidence interval, 0.578-0.878, P=0.042) co
mpared to HBV DNA or HBsAg titer (Fig. 3). The 
sensitivity and specificity of HBsAg/HBV DNA ratio in 
predicting VR were 51.1% and 100%, respectively, at the 
cut-off value of 0.56.
DISCUSSION
Previous studies showed that on-treatment decline of 
HBsAg titer can predict VR during peg-IFN
15-17 or NA 
therapy.
18,20,21 However, it is not established whether pre- 
treatment HBsAg levels can predict VR to antiviral 
drugs. It is controversial whether baseline HBsAg titer 
is a predictor of sustained response after peg-IFN 
therapy.
16,17,24 Lee et al reported that low baseline HBsAg 
levels were associated with VR to entecavir in HBeAg- 
positive CHB,
21 whereas another report showed no 
significant association of pre-treatment HBsAg levels with 
response to telbivudine.
18 Our data also revealed no significant 
association between pre-treatment HBsAg levels and 
VR (P=0.278; Table 2). In contrast, we found that serum 
HBsAg/HBV DNA ratio predict VR better than HBsAg 
level or HBV DNA level in nucleos(t)ide naïve CHB 
patients treated with entecavir (P<0.05; Fig. 3).
Recent reports have demonstrated that serum HBsAg 
levels vary among different stages in the natural history of 
CHB. HBsAg level is the lowest in the low replicative phase 
compared to immune tolerance, immune clearance phase 
and HBeAg negative hepatitis phase.
25,26 Moreover, HBsAg 
production does not change in parallel with HBV DNA 
across the natural history of CHB.
27 Serum HBsAg/HBV 
DNA ratio is higher in the low-replicative phase compared 
to immune-tolerant, immune-clearance and HBeAg negative 
hepatitis phase.
25,26 Dissociation between HBV DNA and 
HBsAg levels may be caused by 1) HBsAg production from 
integrated viral genome in low-level HBV replication stage, 
or 2) preferential control of HBV replication by cytokine 
effects.
27 In either case, high HBsAg/HBV DNA ratio 
may indicate enhanced host immunity which preferentially 
suppresses HBV replication pathway (transcription of 
pregenomic RNA), relatively sparing HBsAg transcrip-
tion.
27,28 If this hypothesis is true, then it is feasible that the 
enhanced host immunity may help to suppress HBV 
replication below undetectable level during entecavir therapy, 
leading to more frequent VR.
We have previously reported that pre-treatment serum 
HBV DNA level is a predictor of virologic response after 
entecavir therapy,
14 and cohort in this paper included part of 
the previous study subjects. However, baseline HBV DNA 
was predictive of VR after 24 months of entecavir therapy 
with only marginal statistical significance (P=0.059; Fig. 2), 
probably due to smaller sample size in this study. There was 
wide overlap of HBV DNA levels between VR (+) and VR 
(-) groups, whereas HBsAg/HBV DNA ratios can better 
differentiate the two groups at the cut-off value of 0.56 by 
ROC analysis (Fig. 3). As this study enrolled limited 
numbers of patients, baseline HBV DNA levels might also 
have been a predictor of virologic response if more patients 
had been enrolled. Further study is warranted to validate the 
superiority of HBsAg/HBV DNA ratio over HBV DNA 
level with larger sample size and longer duration of treatment.
HBsAg levels tend to be higher in HBeAg-positive CHB 
compared to HBeAg-negative CHB in previous studies,
25,26 
whereas the difference was not significant in our data 
(P=0.071; Table 1). The study from Asia reported that 
HBsAg levels are genotype-dependent
25: the difference in 
HBsAg levels tend to be smaller between immune clearance 
and HBeAg-negative CHB in genotype C which is the 
exclusive genotype in Korea. Interestingly, the HBsAg/HBV 
DNA ratios of immune clearance (HBeAg-positive) and 
HBeAg-negative CHB in our study are nearly identical to 
those from those previous studies,
25,26 suggesting that this 
marker may be reproducible regardless of ethnicity or 
genotypes.
Our data shows that pre-treatment HBsAg/HBV DNA 
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(hazard ratio=2.239, P=0.003; Table 3). Pre-treatment predictor 
(HBsAg/HBV DNA ratio) may have clinical advantage over 
on-treatment HBsAg level changes in predicting VR 
because other potent NA (eg. tenofovir) may be tried in 
patients who have low pre-treatment probability of VR to 
entecavir. As our study has not evaluated on-treament 
HBsAg changes, this issue should be elucidated in further 
studies.
In conclusion, pre-treatment serum HBsAg/HBV DNA 
ratio can predict long-term VR to entecavir therapy in 
nucleos(t)ide-naïve CHB patients.
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